A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of ALA-3000, Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Subjects With Treatment-Resistant Depression (TRD)
NCT06965569 · COMPLETED · Phase 1
We track 1 ClinicalTrials.gov studies led by Alar Pharmaceuticals Inc. The portfolio skews toward Phase 1 (1 trials).
1 clinical trials sponsored by Alar Pharmaceuticals Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
Alar Pharmaceuticals Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 1.
Alar Pharmaceuticals Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.